Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL

Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA
The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL ( Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA )
27 Jun 2025

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA
Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
27 Jun 2025

POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA
POLA-R-GEMOX  regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )
27 Jun 2025

ASCO 2025: Importance of early testing in metastatic prostate cancer

Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano
ASCO 2025: Importance of early testing in metastatic prostate cancer ( Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano )
3 Jun 2025

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer

Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy
Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer ( Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy )
3 Jun 2025

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC

Dr David Braun - Yale School of Medicine, New Haven, USA
HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )
2 Jun 2025

New MOAs in prostate cancer treatment - what’s next?

Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini
New MOAs in prostate cancer treatment - what’s next? ( Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini )
2 Jun 2025

Social determinants and survival outcomes in early-onset colorectal cancer in the US

Dr Jessica Paulus - Ontada, Boston, USA
Social determinants and survival outcomes in early-onset colorectal cancer in the US ( Dr Jessica Paulus - Ontada, Boston, USA )
2 Jun 2025

Low frequency of dihydropyrimidine dehydrogenase variants in Mexican GI cancers should induce testing guideline reform

Dr Enrique Soto Pérez de Celis - University of Colorado Cancer Center, Aurora, USA
Low frequency of dihydropyrimidine dehydrogenase variants in Mexican GI cancers should induce testing guideline reform ( Dr Enrique Soto Pérez de Celis - University of Colorado Cancer Center, Aurora, USA )
2 Jun 2025

Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA
Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )
2 Jun 2025

GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for diabetics

Dr Lucas A Mavromatis - NYU Grossman School of Medicine, New York, USA
GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for diabetics ( Dr Lucas A Mavromatis - NYU Grossman School of Medicine, New York, USA )
2 Jun 2025

Neoadjuvant PD-1 blockade enables organ preservation in early dMMR tumours without surgery

Dr Michael Foote - Memorial Sloan Kettering Cancer Center, New York, USA
Neoadjuvant PD-1 blockade enables organ preservation in early dMMR tumours without surgery ( Dr Michael Foote - Memorial Sloan Kettering Cancer Center, New York, USA )
31 May 2025